Contact Dr Alexey Larionov
Background
Alexey Larionov has more than 15 years of experience in applied bioinformatics, with expertise and track record in analysis of a wide range of sequencing data types (including genomics, transcriptomics and metagenomics). Initially educated as a medical doctor in Russia (1992, Bachelor in Medicine recognised by UK NARIC), Alexey became interested in translational research and completed a PhD studying mechanisms and markers of endocrine resistance in breast cancer (1997, Russia, recognised by UK NARIC). Supported by the Royal Society grant, Alexey did his postdoctoral fellowship in Edinburgh University. Working with data-rich experimental methods (qPCR, microarrays, NGS) he became interested in data analysis and switched to bioinformatics. After completion of MSc in Applied Bioinformatics (2012, Cranfield University) Alexey worked as a bioinformatician in Cambridge University, focusing on NGS data analysis and heritable predisposition to cancer. Since 2021 Alexey is a Lecturer in Bioinformatics in Cranfield University. Currently, AL teaches Python, epigenetics, proteomics and metagenomics analysis in Applied Bioinformatics MSc course in Cranfield University, supervises PDRA and PhD students. Alexey is a co-investigator in NERC (Restoring Resilient Ecosystems, NE/V006444/1) and BBSRC (Developing a resilient and regenerative tea production system, BB/Y003241/1) grants. Alexey is a Fellow of The Higher Education Academy (UK). See more details at http://larionov.co.uk
Publications
Articles In Journals
- Sizmur T & Larionov A. (2025). The soil microbial methylome: a tool to explore the role of epigenetic memory in driving soil abiotic legacy effects. Soil Biology and Biochemistry, 202
- Larionov A, Fewings E, Redman J, Goldgraben M, Clark G, .... (2023). The contribution of germline pathogenic variants in breast cancer genes to contralateral breast cancer risk in BRCA1/BRCA2/PALB2-negative women. Cancers, 15(2)
- Yngvadottir B, Andreou A, Bassaganyas L, Larionov A, Cornish AJ, .... (2022). Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Human Molecular Genetics, 31(17)
- Fewings E, Khoo Sert Kim S, Larionov A, Marker A, Giger O, .... (2021). Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review. Endocrine Oncology, 1(1)
- Goldgraben MA, Fewings E, Larionov A, Scarth J, Redman J, .... (2020). Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild‐type TP53 and mutant KRAS, G3BP1 and IL7R. Pediatric Blood & Cancer, 67(9)
- Fewings E, Ziemer M, Hörtnagel K, Reicherter K, Larionov A, .... (2019). Malta (MYH9 Associated Elastin Aggregation) Syndrome: Germline Variants in MYH9 Cause Rare Sweat Duct Proliferations and Irregular Elastin Aggregations. Journal of Investigative Dermatology, 139(10)
- Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, .... (2018). Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. The Lancet Gastroenterology & Hepatology, 3(7)
- Larionov AA. (2018). Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Frontiers in Oncology, 8(APR)
- Goldgraben M, Larionov A, Fewings E, Scarth J, Redman J, .... (2018). PO-061 Exploring heritable predisposition to paediatric rhabdomyosarcomas. ESMO Open, 3
- Flågeng MH, Larionov A, Geisler J, Knappskog S, Prestvik WS, .... (2017). Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. The Journal of Steroid Biochemistry and Molecular Biology, 165(Pt B)
- Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, .... (2015). Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 33(20)
- Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, .... (2015). Personalization of Loco-Regional Care for Primary Breast Cancer Patients (Part 2). Future Oncology, 11(9)
- Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, .... (2015). Personalization of Loco-Regional Care for Primary Breast Cancer Patients (Part 1). Future Oncology, 11(9)
- López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, .... (2015). Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 17(1)
- Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, .... (2014). Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy. Cancer Research, 74(19)
- Sokolenko AP, Bulanova DR, Iyevleva AG, Aleksakhina SN, Preobrazhenskaya EV, .... (2014). High prevalence ofGPRC5Agermline mutations inBRCA1-mutant breast cancer patients. International Journal of Cancer, 134(10)
- Sims AH, Larionov AA, Harrison DJ & Katz E. (2013). Use of Microarray Analysis to Investigate EMT Gene Signatures. Methods in Molecular Biology, 1046
- Kuligina ES, Sokolenko AP, Mitiushkina NV, Abysheva SN, Preobrazhenskaya EV, .... (2013). Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. Familial Cancer, 12(1)
- Turnbull AK, Kitchen RR, Larionov AA, Renshaw L, Dixon JM, .... (2012). Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis. BMC Medical Genomics, 5(1)
- Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, Mitiushkina NV, Abysheva SN, .... (2012). High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. International Journal of Cancer, 130(12)
- Miller WR, Larionov A, Anderson TJ, Evans DB & Dixon JM. (2012). Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. The Pharmacogenomics Journal, 12(1)
- Miller WR & Larionov AA. (2012). Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Research, 14(1)
- Kuligina ES, Sokolenko AP, Mitiushkina NV, Abysheva SN, Preobrazhenskaya EV, .... (2012). Abstract 74: Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation.. Cancer Epidemiology, Biomarkers & Prevention, 21(11_Supplement)
- Flågeng MH, Larionov A, Geisler J, Dixon JM, Lønning PE, .... (2012). Abstract P6-04-06: Inverse regulation of Neuregulin1 and HER-3 during treatment with aromatase inhibitors of estrogen receptor-positive breast cancer. Cancer Research, 72(24_Supplement)
- Larionov A, Turnbull A, Sims A, Renshaw L, Kay C, .... (2012). Abstract P3-06-23: Predicting response to neoadjuvant letrozole. Cancer Research, 72(24_Supplement)
- Miller WR & Larionov A. (2011). Molecular effects of oestrogen deprivation in breast cancer. Molecular and Cellular Endocrinology, 340(2)
- Miller WR & Larionov AA. (2011). Bridging the Gap Between Translational Research and Clinical Application. JNCI Monographs, 2011(43)
- Miller WR & Larionov A. (2010). Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Research, 12(4)
- Hrstka R, Nenutil R, Fourtouna A, Maslon MM, Naughton C, .... (2010). The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene, 29(34)
- Miller WR, Krause A, Larionov A, Evans DB, Anderson TJ, .... (2010). Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole. European journal of Clinical and Medical Oncology, 2(2)
- Larionov AA & Miller WR. (2009). Challenges in Defining Predictive Markers for Response to Endocrine Therapy in Breast Cancer. Future Oncology, 5(9)
- Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, .... (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences, 106(33)
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). Genes Regulated by miRNA in Endocrine-Resistant Breast Tumours.. Cancer Research, 69(24_Supplement)
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). Gene Expression Profiles of Endocrine Resistant Breast Tumours.. Cancer Research, 69(24_Supplement)
- Larionov A, Faratian D, Caldwell H, Sims A, Fawkes A, .... (2009). miRNA Profiling of Endocrine-Resistant Breast Tumours.. Cancer Research, 69(24_Supplement)
- Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, .... (2007). Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenetics and Genomics, 17(10)
- Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, .... (2007). Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Research, 9(3)
- Miller WR, Larionov A, Renshaw L, Anderson TJ, White S, .... (2007). Aromatase inhibitors—Gene discovery. The Journal of Steroid Biochemistry and Molecular Biology, 106(1-5)
- Tomlinson VAL, Newbery HJ, Wray NR, Jackson J, Larionov A, .... (2005). Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer, 5(1)
- Larionov A, Krause A & Miller W. (2005). A standard curve based method for relative real time PCR data processing. BMC Bioinformatics, 6(1)
- Miller WR, Renshaw L, Larionov A, Anderson TJ, White S, .... (2005). Prediction of hormone response in breast cancer by microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant therapy with letrozole. Journal of Clinical Oncology, 23(16_suppl)
- Berstein LM, Kovalevskij A, Larionov A, Tsyrlina E, Vasilyev D, .... (2003). Aromatase activity in receptor negative breast and endometrial cancer. Experimental Oncology, 25(3)
- Larionov AA, Berstein LM & Miller WR. (2002). Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. The Journal of Steroid Biochemistry and Molecular Biology, 81(1)
- Berstein L, Larionov A, Poroshina T, Zimarina T & Leenman E. (2002). Aromatase (CYP19) expression in tumor-infiltrating lymphocytes and blood mononuclears. Journal of Cancer Research and Clinical Oncology, 128(3)
- Berstein L, Maximov S, Gershfeld E, Meshkova I, Gamajunova V, .... (2002). Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. European Journal of Obstetrics & Gynecology and Reproductive Biology, 105(2)
- Bershtein LM, Maksimov SI, Gershfel'd ED, Gamaiunova VB, Tsyrlina EV, .... (2001). Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects. Voprosy onkologii, 47(5)
- Larionov AA, Poroshina TE, Zimarina TS, Leenman EE & Bershtein LM. (2000). Aromatase (estrogen synthetase) gene expression in human leukocytes. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk, 86(1)
- Berstein LM, Larionov AA, Pauley RJ, Chernitsa OI, Semiglazov VF, .... (1999). Aromatase gene expression and its modifying factors in breast tumor tissue. Voprosy onkologii, 45(5)
- Berstein LM, Larionov AA, Chernitsa OI, Kolesnik OS & Manikhas AG. (1998). Aromatase activity and its gene expression in tumor tissue of smokers and non-smokers with breast cancer. Voprosy onkologii, 44(6)
- Larionov AA, Uporov AV, Semiglazov VF & Berstein LM. (1998). Correlation between tumor tissue aromatase, histological pattern and reproductive status in patients with breast cancer. Voprosy onkologii, 44(1)
- Bershtein LM, Poroshina TE, Larionov AA & Zimarina TS. (1998). Metabolism of the androgenic precursor androstenedione and effects of aromatase inhibitors in cultured blood lymphocytes. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk, 84(11)
- Berstein LM, Poroshina TE, Zimarina TS, Larionov AA, Kovalenko IG, .... (1998). Ability of lymphocytes infiltrating breast-cancer tissue to convert androstenedione. International Journal of Cancer, 77(4)
- Bershtein LM, Poroshina TE, Zimarina TS, Larionov AA & Uporov AV. (1997). Conversion of androstenedione in the lymphocytes infiltrating the breast tumor tissue. Biulleten' eksperimental'noi biologii i meditsiny, 124(10)
- Bershtein LM, Poroshina TE, Larionov AA, Zimarina TS & Kryukova OG. (1997). Dexamethasone and dibutyryl-cAMP stimulate androstenedione conversion in human blood lymphocytes. Doklady Akademii Nauk, 352(2)
- Bershtein LM, Poroshina TE, Zimarina TS, Larionov AA & Uporov AV. (1997). Androstenedione conversion in lymphocytes infiltrating breast tumor tissue. Bulletin of Experimental Biology and Medicine, 124(4)
- Berstein LM, Larionov AA, Kyshtoobaeva AS, Pozharisski KM, Semiglazov VF, .... (1996). Aromatase in breast cancer tissue ? localization and relationship with reproductive status of patients. Journal of Cancer Research and Clinical Oncology, 122(8)
- Berstein LM, Kovalenko IG, Tsyrlina YV & Larionov AA. (1996). Catecholamine excretion in smoking female breast cancer patients: A possible relation to the mechanisms of hormonal carcinogenesis. Experimental Oncology, 18(2)
- Bershtein LM, Poroshina TE, Tsyrlina EV, Gamaiunova VB, Kovalenko IG, .... (1996). Correlation of lymphocytic infiltration of tumor tissue with the hormonal and metabolic state in patients with breast cancer. Voprosy onkologii, 42(5)
- Berstein LM, Larionov AA, Krjukova OG, Kochev VA & Semiglasov VF. (1996). Investigation of aromatase activity in human muscle tissue. Voprosy Meditsinskoj Khimii, 42(1)
- Berstein LM, Kovalenko IG, Tsyrlina YV & Larionov AA. (1996). Catecholamine excretion in smoking female breast cancer patients: A possible relation to the mechanisms of hormonal carcinogenesis. EXPERIMENTAL ONCOLOGY, 18(3)
- Bershtein LM, Larionov AA, Kryshtoobaeva AS, Pozharisskii KM & Semiglazov VF. (1995). Aromatase activity in breast cancer tissue: the role of a cellular substrate. Biulleten' eksperimental'noi biologii i meditsiny, 120(10)
- Bershtein LM, Larionov AA, Kyshtoobaeva AS, Pozharisskii KM & Semiglazov VF. (1995). Activity of aromatase in breast cancer tissue: Role of the cell substrate. Bulletin of Experimental Biology and Medicine, 120(4)
- Bershteǐn LM, Tsyrlina EV, Semiglazov VF, Larionov AA, Kovalenko IG, .... (1994). Adipose and lean body mass in obese pre- and post-menopausal patients with breast cancer: the modifying role of smoking. Voprosy Onkologii, 40(7-12)
- Bershtein LM, Larionov AA & Kryukova OG. (1994). Androstenedione conversion in human peripheral blood lymphocytes. Bulletin of Experimental Biology and Medicine, 117(5)
- Khirmanov VN, Kireenkov IS, Berkovich OA, Larionov AA, Kornilov NV, .... (1993). Changes in the concentration of atrial hormone in hypertensive crises. Klinicheskaya Meditsina, 71(3)